

## Indonesia Support for Inactivated Polio Vaccine (IPV)

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Indonesia				
<b>2. Grant number:</b> 1618-IDN-25b-Y				
<b>3. Date of Decision Letter:</b> 22 May 2017 (Replaces the previous Decision Letter for IPV dated 14 February 2017)				
<b>4. Date of the Partnership Framework Agreement:</b> 30 December 2014				
<b>5. Programme title:</b> NVS, IPV routine				
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)				
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID				
<b>8. Programme duration<sup>2</sup>:</b> 2016 - 2018				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement) <i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>				
	2016	2017	2018	Total <sup>3</sup>
Programme Budget (US\$)	US\$4,165,000	US\$6,647,000	US\$8,141,000	US\$18,953,000
<b>10. Vaccine introduction grant (in US\$):</b> US\$3,688,500 was disbursed on 28 November 2014				
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>4</sup>				
Type of supplies to be purchased with Gavi funds in each year	2016	2017		
Number of IPV vaccines doses		3,400,000		
Annual Amounts (US\$)	US\$4,165,000	US\$6,647,000		
<b>12. Procurement agency:</b> Not applicable				
<b>13. Self-procurement:</b> Country has elected to self-procure vaccines and injection safety devices in lieu of procuring through a Gavi agency. The applicable terms of the Partnership Framework Agreement and relevant Gavi guidelines and policies on self-procurement shall apply.				

<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2016 to 2018.

<sup>4</sup> This is the amount that Gavi has approved.

<p><b>14. Co-financing obligations:</b> Not applicable</p> <p>Gavi's usual co-financing requirements do not apply to IPV. However, Indonesia is encouraged to contribute to vaccine and/or supply costs for IPV.</p>									
<p><b>15. Operational support for campaigns:</b> Not applicable</p>									
<p><b>16. Additional reporting requirements:</b></p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> <tr> <td>Following self-procurement, Country must submit full report outlining the total quantities of vaccine, supply chain equipment and injection safety devices, as applicable, procured, and final costs to be compared against the budget allocated in this Decision Letter. Country must submit satisfactory evidence that it purchased the vaccine doses and related supplies communicated by Gavi in this Decision Letter, by submitting purchase orders, invoices and receipts. Any balance of Gavi funds disbursed in support of Country self-procurement should be reported to Gavi together with satisfactory evidence that the leftover funds have been used within the immunisation programme.</td> <td></td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	Following self-procurement, Country must submit full report outlining the total quantities of vaccine, supply chain equipment and injection safety devices, as applicable, procured, and final costs to be compared against the budget allocated in this Decision Letter. Country must submit satisfactory evidence that it purchased the vaccine doses and related supplies communicated by Gavi in this Decision Letter, by submitting purchase orders, invoices and receipts. Any balance of Gavi funds disbursed in support of Country self-procurement should be reported to Gavi together with satisfactory evidence that the leftover funds have been used within the immunisation programme.	
Reports and other information	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
Following self-procurement, Country must submit full report outlining the total quantities of vaccine, supply chain equipment and injection safety devices, as applicable, procured, and final costs to be compared against the budget allocated in this Decision Letter. Country must submit satisfactory evidence that it purchased the vaccine doses and related supplies communicated by Gavi in this Decision Letter, by submitting purchase orders, invoices and receipts. Any balance of Gavi funds disbursed in support of Country self-procurement should be reported to Gavi together with satisfactory evidence that the leftover funds have been used within the immunisation programme.									
<p><b>17. Financial clarifications:</b> Not applicable</p>									
<p><b>18. Other conditions:</b></p> <p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual number of doses shipped may differ from the amounts specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p>									

Signed by,  
On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
22 May 2017